supercomputer
Eli Lilly and Company says the partnership will result in the development of the most powerful supercomputer owned by a pharmaceutical company.
The round follows a $200 million seed raise earlier this year.
They aim to bring down the period and costs for new drug development.
The £40 million system is intended to enable researchers to tackle the most pressing medical challenges.